(DOC) Healthpeak Properties - Overview
Stock: Outpatient Medical, Lab, CCRC, Joint Venture Loans
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 7.34% |
| Yield on Cost 5y | 7.31% |
| Yield CAGR 5y | -12.85% |
| Payout Consistency | 96.7% |
| Payout Ratio | 504.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 26.3% |
| Relative Tail Risk | -2.70% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.66 |
| Alpha | -23.95 |
| Character TTM | |
|---|---|
| Beta | 0.465 |
| Beta Downside | 0.641 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.51% |
| CAGR/Max DD | -0.22 |
Description: DOC Healthpeak Properties January 03, 2026
Healthpeak Properties, Inc. (NYSE: DOC) is an S&P 500-listed REIT that owns, operates, and develops a diversified portfolio of U.S. healthcare real estate across three core segments: outpatient medical facilities, laboratory spaces, and continuing-care retirement communities (CCRCs). Structured as an umbrella partnership REIT (UPREIT), the company holds the vast majority of its assets through its operating subsidiary, Healthpeak OP, and reports a total of 703 property interests as of September 30 2025, including 530 outpatient, 139 lab, 15 CCRC, and 19 non-reportable assets.
Key performance indicators from the most recent fiscal year show a funds-from-operations (FFO) of approximately $1.10 per share and an occupancy rate near 96% across the portfolio, reflecting strong demand for outpatient and lab space. The REIT’s leverage ratio remains around 45% of total assets, a level that analysts consider moderate given the sector’s sensitivity to interest-rate movements. Demographic trends-particularly the aging U.S. population and the shift toward outpatient care-continue to drive demand for Healthpeak’s property types, while the company’s dividend yield hovers near 5.5%.
For a deeper dive into Healthpeak’s valuation metrics, you might explore the detailed analyst toolkit on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -38.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.24 > 1.0 |
| NWC/Revenue: -5.18% < 20% (prev -26.16%; Δ 20.98% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.24b > Net Income -38.1m |
| Net Debt (9.34b) to EBITDA (1.52b): 6.14 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (696.4m) vs 12m ago -0.54% < -2% |
| Gross Margin: 60.08% > 18% (prev 0.60%; Δ 5948 % > 0.5%) |
| Asset Turnover: 14.16% > 50% (prev 12.80%; Δ 1.36% > 0%) |
| Interest Coverage Ratio: 1.53 > 6 (EBITDA TTM 1.52b / Interest Expense TTM 295.0m) |
Altman Z'' -1.35
| A: -0.01 (Total Current Assets 981.7m - Total Current Liabilities 1.13b) / Total Assets 19.58b |
| B: -0.30 (Retained Earnings -5.85b / Total Assets 19.58b) |
| C: 0.02 (EBIT TTM 451.0m / Avg Total Assets 19.78b) |
| D: -0.46 (Book Value of Equity -5.17b / Total Liabilities 11.32b) |
| Altman-Z'' Score: -1.35 = CCC |
Beneish M -3.09
| DSRI: 0.93 (Receivables 754.3m/742.6m, Revenue 2.80b/2.56b) |
| GMI: 1.00 (GM 60.08% / 60.01%) |
| AQI: 1.00 (AQ_t 0.93 / AQ_t-1 0.93) |
| SGI: 1.10 (Revenue 2.80b / 2.56b) |
| TATA: -0.07 (NI -38.1m - CFO 1.24b) / TA 19.58b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of DOC shares?
Over the past week, the price has changed by -7.11%, over one month by +0.95%, over three months by -5.33% and over the past year by -13.17%.
Is DOC a buy, sell or hold?
- StrongBuy: 10
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DOC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.2 | 22.6% |
| Analysts Target Price | 20.2 | 22.6% |
| ValueRay Target Price | 16.9 | 2.7% |
DOC Fundamental Data Overview February 03, 2026
P/S = 4.2772
P/B = 1.5679
P/EG = 4.0809
Revenue TTM = 2.80b USD
EBIT TTM = 451.0m USD
EBITDA TTM = 1.52b USD
Long Term Debt = 8.76b USD (from longTermDebt, last quarter)
Short Term Debt = 368.1m USD (from shortTermDebt, last quarter)
Debt = 9.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.34b USD (from netDebt column, last quarter)
Enterprise Value = 21.32b USD (11.98b + Debt 9.43b - CCE 91.0m)
Interest Coverage Ratio = 1.53 (Ebit TTM 451.0m / Interest Expense TTM 295.0m)
EV/FCF = 17.18x (Enterprise Value 21.32b / FCF TTM 1.24b)
FCF Yield = 5.82% (FCF TTM 1.24b / Enterprise Value 21.32b)
FCF Margin = 44.32% (FCF TTM 1.24b / Revenue TTM 2.80b)
Net Margin = -1.36% (Net Income TTM -38.1m / Revenue TTM 2.80b)
Gross Margin = 60.08% ((Revenue TTM 2.80b - Cost of Revenue TTM 1.12b) / Revenue TTM)
Gross Margin QoQ = 58.64% (prev 60.22%)
Tobins Q-Ratio = 1.09 (Enterprise Value 21.32b / Total Assets 19.58b)
Interest Expense / Debt = 0.81% (Interest Expense 76.8m / Debt 9.43b)
Taxrate = 1.60% (4.35m / 271.7m)
NOPAT = 443.8m (EBIT 451.0m * (1 - 1.60%))
Current Ratio = 0.87 (Total Current Assets 981.7m / Total Current Liabilities 1.13b)
Debt / Equity = 1.24 (Debt 9.43b / totalStockholderEquity, last quarter 7.60b)
Debt / EBITDA = 6.14 (Net Debt 9.34b / EBITDA 1.52b)
Debt / FCF = 7.53 (Net Debt 9.34b / FCF TTM 1.24b)
Total Stockholder Equity = 8.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.19% (Net Income -38.1m / Total Assets 19.58b)
RoE = -0.47% (Net Income TTM -38.1m / Total Stockholder Equity 8.03b)
RoCE = 2.69% (EBIT 451.0m / Capital Employed (Equity 8.03b + L.T.Debt 8.76b))
RoIC = 2.62% (NOPAT 443.8m / Invested Capital 16.97b)
WACC = 4.62% (E(11.98b)/V(21.41b) * Re(7.63%) + D(9.43b)/V(21.41b) * Rd(0.81%) * (1-Tc(0.02)))
Discount Rate = 7.63% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 12.79%
[DCF Debug] Terminal Value 87.31% ; FCFF base≈1.15b ; Y1≈1.28b ; Y5≈1.67b
Fair Price DCF = 57.41 (EV 49.24b - Net Debt 9.34b = Equity 39.90b / Shares 694.9m; r=5.90% [WACC]; 5y FCF grow 12.72% → 2.90% )
EPS Correlation: -44.06 | EPS CAGR: -7.16% | SUE: -0.69 | # QB: 0
Revenue Correlation: 95.18 | Revenue CAGR: 10.63% | SUE: 2.35 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.09 | Chg30d=+0.001 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=0.25 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+2600.0% | Growth Revenue=+1.5%